{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:16:02Z","timestamp":1787786162450,"version":"build-2784847793"},"reference-count":84,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Recent treatment advancements in multiple myeloma have led to significant improvements in patient outcomes. Maintenance therapy following autologous haematopoietic stem cell transplantation (AHCT) is now standard of care and has been demonstrated to prolong and deepen treatment responses. Currently, lenalidomide remains the single agent that has been approved for maintenance post\u2010AHCT in Europe and the USA which, if tolerated, is continued until disease progression. The treatment landscape is rapidly expanding however, and the optimal personalised maintenance approach for a patient is becoming more complex. Treatment outcomes for patients with high\u2010risk disease remain poor and choice of maintenance in this population also remains unclear. This review article evaluates up\u2010to\u2010date literature regarding established maintenance approaches. It further analyses ongoing studies exploring maintenance regimens using combination and novel agents, approaches to maintenance in patients with cytogenetic high\u2010risk disease and minimal residual disease response\u2010adapted strategies that reflect the current evolving treatment paradigm.<\/jats:p>","DOI":"10.1111\/bjh.19353","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T10:38:54Z","timestamp":1708684734000},"page":"1159-1175","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the <scp>EBMT<\/scp>"],"prefix":"10.1111","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4938-0910","authenticated-orcid":false,"given":"Angela","family":"Hwang","sequence":"first","affiliation":[{"name":"Department of Haematology University College London Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1374-4503","authenticated-orcid":false,"given":"Patrick","family":"Hayden","sequence":"additional","affiliation":[{"name":"Department of Haematology St James's Hospital  Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-0028","authenticated-orcid":false,"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-091X","authenticated-orcid":false,"given":"Donal","family":"McLornan","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6138-8112","authenticated-orcid":false,"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'H\u00e9matologie H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30140-0"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402888"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00389-7"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0724-1"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134538"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165376"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-357038"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.39.39"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30149-2"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000786"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18772"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0620-8"},{"key":"e_1_2_6_19_1","unstructured":"ClinicalTrials.gov.Iberdomide Maintenance Therapy in Patients With Multiple Myeloma [Internet]. 2023. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05177536"},{"key":"e_1_2_6_20_1","unstructured":"ClinicalTrials.gov.Iberdomide (CC220) Maintenance After ASCT in Newly Diagnosed MM Patients [Internet]. 2022. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04564703"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379164"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.35"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.335"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e20053"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01691-1"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146798"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019531"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280394"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3420"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00535-0"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00738-0"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007522"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00428-9"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137109"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122471"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142913"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8055"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-191911"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00263-0"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01431-x"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147323"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139934"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30354-9"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162584"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165526"},{"key":"e_1_2_6_50_1","unstructured":"ClinicalTrials.gov.Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients with Relapse Refractory Multiple Myeloma [Internet]. 2023. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05065047"},{"key":"e_1_2_6_51_1","unstructured":"ClinicalTrials.gov.Minimal Residual Disease Guided Maintenance Therapy with Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma [Internet]. 2023. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05091372"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01338-6"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159711"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159756"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150519"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8066"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00693-3"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046225"},{"key":"e_1_2_6_59_1","unstructured":"ClinicalTrials.gov.Ixazomib Plus Low\u2010dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma [Internet]. 2023. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05722405"},{"key":"e_1_2_6_60_1","unstructured":"ClinicalTrials.gov.VRD as Induction Followed by VR Maintenance in Patients with Newly Diagnosed High Risk Multiple Myeloma [Internet]. 2023. Available from:https:\/\/clinicaltrials.gov\/study\/NCT03641456"},{"key":"e_1_2_6_61_1","unstructured":"ClinicalTrials.gov.Expression\u2010linked and R\u2010ISS\u2010adapted Stratification for First Line Therapy in Multiple Myeloma Patients (ELIAS) [Internet]. 2023. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05665140"},{"key":"e_1_2_6_62_1","unstructured":"ClinicalTrials.gov.Post\u2010Transplant Maintenance Therapy with Isatuximab Plus Lenalidomide for High\u2010Risk Multiple Myeloma Patients [Internet]. 2023. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05776979"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018339"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.07.028"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02567"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016782"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02228"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006731"},{"key":"e_1_2_6_70_1","first-page":"435","article-title":"Minimal residual disease in multiple myeloma: final analysis of the IFM2009 trial","volume":"130","author":"Avet\u2010Loiseau H","year":"2017","journal-title":"Blood"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019531"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169937"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158643"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970348.49945.47"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-156730"},{"key":"e_1_2_6_76_1","unstructured":"ClinicalTrials.gov.Minimal Residual Disease Guided Maintenance Therapy with Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma [Internet]. 2023."},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165209"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.332"},{"key":"e_1_2_6_79_1","unstructured":"ClinicalTrials.gov.MInimal Residual Disease Adapted Strategy (MIDAS) [Internet]. 2023. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04934475"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170936"},{"key":"e_1_2_6_81_1","unstructured":"ClinicalTrials.gov.Post\u2010Autologous Transplant Maintenance with Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma (HEME\u201018) [Internet]. 2023. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05344833"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168842"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970740.31629.41"},{"key":"e_1_2_6_84_1","unstructured":"ClinicalTrials.gov.Elotuzumab in Combination with Carfilzomib Lenalidomide and Dexamethasone (E\u2010KRd) Versus KRd in MM [Internet]. 2023. Available from:https:\/\/clinicaltrials.gov\/study\/NCT03948035"},{"key":"e_1_2_6_85_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8055"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T15:37:34Z","timestamp":1712763454000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/bjh.19353"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19353","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"2023-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}